Weight-Loss Drug Qsymia® Linked to Stevens-Johnson Syndrome
The team at Fibich, Leebron, Copeland & Briggs is now actively reviewing cases from those who may have suffered adverse health effects through the use of popular weight loss drug Qsymia®. Qsymia is gaining an increasing amount of attention over its potential to cause serious side effects, including a particularly dreadful skin disease called Stevens-Johnson Syndrome.
What is Qsymia?
Manufactured by the California-based pharmaceutical company Vivus, Qsymia is a drug for chronic weight management that works by suppressing a user’s appetite. Although the drug is FDA-approved, it can cause a host of side effects ranging from eye problems, birth defects, and metabolic acidosis to suicidal thoughts and seizures.
One of the most serious side effects linked to Qsymia use is Stevens-Johnson Syndrome (or SJS), a rare skin disease that results in cell death and causes the layers of the skin to separate. SJS can lead to Toxic Epidermal Necrolysis (TEN), another skin disorder with seriously damaging effects including blistering, discoloration, and exfoliation of the skin, hives and burns, shedding of nails and hair, and in the most serious instances, even damage to internal organs and loss of eyesight.
Stevens-Johnson Syndrome can cause great pain and permanent scarring and can in some cases be life-threatening. Recovering from such a serious illness can take weeks, months, or even years, in which costly medical bills can begin to pile up.Qsymia
Pharmaceutical Litigation Attorneys in Houston, TX
You shouldn’t have to suffer for using a dangerous product that has been marketed as safe for use. If you or a loved one have taken Qsymia and suffered any kind of adverse side effect, including SJS, your rights are protected under product liability law and you can be eligible to claim compensation for your medical care and pain and suffering. Fibich, Leebron, Copeland & Briggs are available to review your case and inform you of your legal options during a free consultation.
Share This Article: